Array BioPharma announced that John A. Orwin, CEO of Affymax, Inc., has joined the company’s Board of Directors. This development is part of Array’s continued evolution toward late-stage development and commercialization.
Throughout his career, Mr. Orwin has built successful businesses and commercialized a range of blockbuster products. Mr. Orwin has served as Affymax’s CEO since 2011, after joining the company in 2010 as its COO. At Affymax, he led the approval and launch of Omontys®, a hematology product for the treatment of anemia in chronic kidney disease. Prior to joining Affymax, he led Genentech’s BioOncology business unit and grew a portfolio of cancer-fighting products to over $7 billion in U.S. sales.
Ron Squarer, Array’s CEO, remarked, “At a time when Array is moving towards commercialization of our pipeline, John has the perfect background to complement the expertise of our board of directors. His track record of building successful sales and marketing teams in oncology for major pharma companies, along with building brands that are respected by physicians and patients alike, will be invaluable as we focus our efforts in oncology and continue our evolution to late-stage development and commercialization.”
Mr. Orwin added, “I have admired Array and the way it has built and advanced an impressive development pipeline. I’m honored to join the company’s board at such an important time in its history, when it is poised to transition to late-stage development, and ultimately commercialization of its drugs. I look forward to working with Ron and my fellow board members to make this happen.”
To learn more about Array BioPharma, visit www.arraybiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
